At a Glance
| Indication | Cancer |
| Company | GE HealthCare |
| Category | Corporate & Strategic |
| Sub Category | Acquisition Announced |
| Therapeutic Area | Oncology |
| Deal Value | $945 million |
| Target Company | Sofie Biosciences |
| Acquisition Type | Cash acquisition |
| Expected Closing | First half of 2027 |
| Target Company Business | Contract manufacturing organization for PET radiopharmaceuticals |
| Number of CMO Sites | 15 across the U.S. |
| Key Product Type | F18-labeled PET products |
| Pipeline Asset Acquired | FAPI-74 (U.S. rights) |
| Existing Product Manufactured | Flyrcado F18 injection product |
| Published Date | Oct. 6, 2026 |
GE HealthCare Acquires Sofie Biosciences for $945M
GE HealthCare announced its agreement to acquire Sofie Biosciences for $945 million in cash. This strategic move aims to significantly expand GE HealthCare’s presence in the U.S. radiopharmaceutical industry, particularly in the manufacturing and distribution of time-sensitive F18-labeled PET products. Sofie Biosciences, a contract manufacturing organization with 15 U.S. sites, specializes in PET radiopharmaceuticals used in medical imaging and disease treatment. The acquisition, expected to close in the first half of 2027, will integrate Sofie Biosciences into GE HealthCare’s pharmaceutical diagnostics business, enhancing its capabilities and pipeline, including U.S. rights to the pan-cancer PET radiotracer FAPI-74.
- GE HealthCare's acquisition of Sofie Biosciences for $945 million in cash is a strategic move to bolster its U.S. radiopharmaceutical capabilities. Sofie Biosciences, a contract manufacturing organization (CMO) with 15 sites, specializes in producing PET radiopharmaceuticals, which are crucial for medical imaging and treating various diseases. This deal provides GE HealthCare with a vital manufacturing and distribution network for time-sensitive F18-labeled PET products.
- The acquisition will integrate Sofie Biosciences into GE HealthCare’s pharmaceutical diagnostics business (PDx), expanding its capacity for F18 radiopharmaceutical products. It also grants GE HealthCare U.S. rights to FAPI-74, a pipeline pan-cancer PET radiotracer, complementing its existing rights outside the U.S. Sofie Biosciences will continue to operate as an independent manufacturing partner, supplying its current portfolio while contributing to GE HealthCare's growth.
- The deal, anticipated to close in the first half of 2027, is expected to contribute to GE HealthCare’s revenue growth and adjusted earnings per share in the first full year of ownership. Analysts note that the added manufacturing and distribution capacity from Sofie Biosciences could help alleviate bottlenecks in the radiopharmaceutical adoption cycle, supporting broader access to these critical diagnostic and therapeutic agents.
Frequently Asked Questions
What are the top 3 treatments for cancer?
The primary treatment modalities for cancer include surgery, radiation therapy, and systemic drug therapies. Surgery is often curative for localized solid tumors, while radiation therapy targets specific areas with high-energy beams. Systemic drug therapies, encompassing chemotherapy, targeted agents, and immunotherapies, treat cancer throughout the body and are selected based on tumor biology and patient profile.
What is the hardest cancer to cure?
While no single cancer is universally the "hardest" to cure, pancreatic adenocarcinoma consistently presents the most significant challenges due to its aggressive biology, late-stage diagnosis, and inherent resistance to conventional therapies, resulting in exceptionally low 5-year survival rates. Glioblastoma also ranks among the most intractable, given its infiltrative nature within the brain and the formidable blood-brain barrier impeding drug delivery. Ultimately, metastatic disease across many cancer types significantly complicates curative intent.
What happens if you don't treat cancer?
Untreated cancer typically progresses through uncontrolled cellular proliferation, leading to increased tumor burden, local invasion, and distant metastasis. This compromises vital organ function, exacerbates debilitating symptoms such as pain, fatigue, and cachexia, and ultimately results in significant morbidity and mortality.
What are five possible treatments for cancer?
Key cancer treatments encompass localized approaches like surgery and radiation therapy, alongside systemic interventions such as chemotherapy. More recently, targeted therapies, which block specific molecular pathways involved in cancer growth, and immunotherapies, which harness the body's immune system to fight cancer, have become pivotal in oncology.
What are the most promising new cancer treatments?
Immunotherapies, including advanced CAR T-cell therapies and novel checkpoint inhibitors, continue to show significant promise, particularly in combination strategies across various malignancies. Targeted therapies, such as next-generation antibody-drug conjugates (ADCs) and highly specific inhibitors for previously undruggable targets like KRAS, are revolutionizing precision oncology. Additionally, bispecific antibodies and emerging gene editing technologies are expanding the therapeutic landscape, offering new avenues for durable responses.
What is the newest form of cancer treatment?
The newest forms of cancer treatment often leverage advanced genetic and cellular engineering. This includes CRISPR-based gene editing for highly precise *ex vivo* modification of immune cells for enhanced adoptive cell therapies, and emerging *in vivo* applications directly targeting tumor cells or their microenvironment. Additionally, personalized mRNA cancer vaccines represent a cutting-edge modality, moving into later-stage clinical trials to stimulate patient-specific anti-tumor immunity.
What is the average life expectancy after stopping cancer treatment?
There is no single average life expectancy after stopping cancer treatment, as outcomes are highly variable. Key determinants include the reason for treatment cessation (e.g., completion of curative therapy, disease progression, intolerable toxicity), the specific cancer type and stage, and the patient's overall health status. For patients in remission after curative intent treatment, life expectancy can approach that of the general population, while for those stopping due to refractory or advanced disease, it may be significantly limited.
What cancer is closest to being cured?
Acute Promyelocytic Leukemia (APL) demonstrates exceptionally high cure rates, often exceeding 90%, through targeted differentiation therapy with all-trans retinoic acid (ATRA) and arsenic trioxide. This approach has transformed APL from a highly fatal disease into one with excellent long-term survival, frequently without intensive cytotoxic chemotherapy. Other cancers with very high curability, especially when diagnosed early, include testicular cancer and papillary thyroid carcinoma.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
